A Phase 0 clinical study with TTX-MC138
Latest Information Update: 15 Dec 2023
At a glance
- Drugs TTX-MC138 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors TransCode Therapeutics
Most Recent Events
- 15 Dec 2023 New trial record